Cardiac Biomarkers in Ischemic Heart Disease (IHD)

1. Overview

2. Cardiac Biomarkers Used in IHD

A. Cardiac Troponins (cTnI and cTnT) — Gold Standard

• cTnT and cTnI have amino-acid sequences distinct from skeletal muscle isoforms, enabling highly specific monoclonal antibody-based immunoassays.
• Detected using high-sensitivity (hs-cTn) assays, which are now the preferred biochemical markers for MI.
• cTnI/cTnT typically remain elevated for 7–10 days after STEMI.
• Rise and fall pattern distinguishes acute myocardial injury from chronic elevation (e.g., renal disease, structural heart disease).
• Serial measurements at presentation and 1–3 h (hs assays) or 3–6 h (conventional assays) are standard.
• Rapid rule-out protocols using hs-cTn at 0 and 1–2 h have negative predictive value >99% when a very low concentration is seen on first sampling (>2–3 h after symptom onset). — Harrison's 22E

B. Creatine Kinase-MB (CK-MB)

• CK-MB (MB isoenzyme of creatine kinase) was historically the standard biomarker for AMI.
• A relative index (CK-MB mass / total CK activity) ≥2.5 suggests, but is not diagnostic of, a myocardial source.
• More rapid decline after AMI onset compared to troponin — making it useful for detecting early reinfarction during the period troponin remains elevated.
• Not cost-effective to measure both a cardiac-specific troponin and CK-MB simultaneously.
• Poor specificity in trauma patients: elevated in skeletal muscle, liver, diaphragm, or intestinal injury. — Harrison's 22E; Tintinalli's Emergency Medicine

C. Myoglobin

• Early-rising biomarker (appears within 1–2 h of onset).
• Lacks cardiac specificity — also released from skeletal muscle injury.
• Largely replaced by hs-cTn for early rule-out; rarely used alone.

D. B-type Natriuretic Peptide (BNP) / NT-proBNP

• Released primarily from ventricular myocytes in response to increased wall stress/volume overload.
• Not a primary marker for MI diagnosis, but used for risk stratification and heart failure diagnosis in the context of IHD-related LV dysfunction.
• NT-proBNP has a longer half-life; BNP has a half-life of ~13–20 minutes.
• Useful when assessed alongside clinical history and examination for diagnosing HF in IHD patients. — Tietz Textbook of Laboratory Medicine 7E; Harrison's 22E

E. High-Sensitivity Troponin Assay — Key Advances

• Allows detection of myocardial injury in a larger proportion of patients with non-ACS cardiopulmonary conditions.
• Greater negative predictive value than conventional assays.
• Rise/fall delta criterion is crucial to distinguish acute from chronic troponin elevation. — Harrison's 22E

3. Biomarker Release Kinetics in AMI

• Release timing depends on: intracellular location, molecular weight, and local blood/lymphatic flow.
• Biomarkers become detectable once cardiac lymphatic clearance capacity is exceeded and spillover into venous circulation occurs.
• Reperfusion (thrombolysis or PCI) causes earlier peaking due to rapid washout — "washout peak." — Harrison's 22E

Classification of elevated cTn: dynamic vs. stable, ischemic vs. non-ischemic injury — Harrison's 22E

4. Preanalytical Variables Affecting Cardiac Biomarkers

A. Sample Type and Anticoagulants

• EDTA and heparin are both known to interfere with cTnI and cTnT antibody-binding affinity and produce matrix effect differences between whole blood, plasma, and serum specimens.
• For emergency processing, anticoagulated whole blood or plasma is the optimal specimen — it eliminates extra clotting time and reduces sample handling.
• Different sample types (e.g., serum vs. plasma) should not be mixed during serial, timed sampling for MI rule-in/rule-out. — Tietz Textbook of Laboratory Medicine 7E

B. Specimen Integrity

• Hemolysis: Can falsely elevate or interfere with immunoassay readings; must be documented.
• Lipemia: Can cause light-scattering interference in photometric-based assays.
• Icterus: Bilirubin can interfere with colorimetric methods.

C. Troponin Degradation / Proteolysis

• cTnI undergoes extensive in vitro proteolysis post-sample collection (Western blot analyses confirm progressive fragmentation over hours at 37°C).
• Antibody epitope selection critically determines how much circulating degraded cTn is detected — different antibody pairs on different assays detect varying amounts of fragmented cTn. — Tietz Textbook of Laboratory Medicine 7E

D. cTn Molecular Forms in Circulation

• Troponin circulates in multiple molecular forms: free cTnI, free cTnT, binary complexes (cTnI-cTnC), ternary complexes (cTnI-cTnT-cTnC), and various phosphorylated/oxidized forms.
• Post-MI, the proportion of the ternary ITC complex decreases over time.
• Different assay antibodies may not detect all circulating forms equally — a source of inter-assay discordance.

E. Assay Standardization Issues

• No primary reference material currently exists for cTnI standardization.
• Results are not interchangeable between assays from different (or even the same) manufacturers.
• cTnT has a single manufacturer (Roche), improving comparability; cTnI assays vary widely.
• NIST developed SRM 2921 (cTnI reference material) but it is of limited practical use for harmonization. — Tietz Textbook of Laboratory Medicine 7E

F. Turnaround Time (TAT)

• Guidelines recommend TAT <60 minutes from order to report.
• Studies (CAP Q-Probe, 159 hospitals) showed median TAT of 74.5 min for troponin, with <25% of hospitals meeting the 60-min target.
• Point-of-care (POC) testing can reduce TAT to <30 minutes, particularly valuable in EDs without rapid central laboratory access. — Tietz Textbook of Laboratory Medicine 7E

G. BNP/NT-proBNP Specific Preanalytical Issues (IFCC C-CB Recommendations 2019)

• Analytical and preanalytical quality specifications for natriuretic peptide (NP) assays were formalized by the IFCC Committee on Clinical Applications of Cardiac Bio-Markers (C-CB).
• Glycosylation of proBNP at Thr-71 affects processing: in acute HF, less glycosylation allows more efficient conversion to NT-proBNP and bioactive BNP; in chronic HF, more glycosylation impairs this, resulting in less active BNP.
• A growing diversity of BNP/NT-proBNP assays exist worldwide — results are not interchangeable between platforms. — Tietz Textbook of Laboratory Medicine 7E

5. Summary Table: Biomarkers in IHD